• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Advaxis, Inc.

    6/4/21 4:30:42 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care
    Get the next $ADXS alert in real time by email
    8-K 1 form8-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 3, 2021

     

    ADVAXIS, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36138   02-0563870

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    9 Deer Park Drive, Suite K-1

    Monmouth Junction, NJ

    08852
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (609) 452-9813

     

     
    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    [  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    [  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.001 per share   ADXS   Nasdaq Capital Market
    Preferred Stock Purchase Right   -   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company [  ]

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 3, 2021, at the 2021 Annual Meeting of Stockholders of Advaxis, Inc. (the “Company”), the Company’s stockholders approved an Amendment to the Advaxis, Inc. 2015 Incentive Plan (the “Amendment”), which was previously approved, subject to stockholder approval, by the Board of Directors (the “Board”) of the Company on February 11, 2021. The Amendment increases the existing per-participant annual award limitations under the Company’s 2015 Incentive Plan to those set forth below:

     

      ●   Options. The maximum number of options granted under the 2015 Incentive Plan in any calendar year to any one participant shall be for 1,000,000 shares.
           
      ●   Stock Appreciation Rights. The maximum number of stock appreciation rights granted under the 2015 Incentive Plan in any calendar year to any one participant shall be with respect to 750,000 shares.
           
      ●   Performance Awards. With respect to any calendar year (i) the maximum amount that may be paid to any one participant for performance awards payable in cash or property other than shares shall be $10,000,000, and (ii) the maximum number of shares that may be paid to any one participant for performance awards payable in stock shall be 1,000,000 shares. For purposes of applying these limits in the case of multi-year performance periods, the amount of cash or property or number of shares deemed paid with respect to any calendar year is the total amount payable or shares earned for the performance period divided by the number of calendar years in the performance period.
           
      ●   Awards to Non-Employee Directors. The maximum aggregate number of shares associated with any award granted under the 2015 Incentive Plan in any calendar year to any of the Company’s non-employee directors shall be 200,000 shares.

     

    Except for the increases to the existing annual award limitations under the 2015 Incentive Plan, as described above, the Amendment does not have any effect on the other provisions of the 2015 Incentive Plan.

     

    The foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment which is attached to this Current Report on Form 8-K as Exhibit 10.1.

     

    Item 9.01 Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Amendment to the Advaxis, Inc. 2015 Incentive Plan, dated as of February 11, 2021

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    June 4, 2021 ADVAXIS, INC.
         
      By: /s/ Kenneth A. Berlin
      Name: Kenneth A. Berlin
      Title: President and Chief Executive Officer and Interim Chief Financial Officer

     

     

     

    Get the next $ADXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

    MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp

    5/9/24 4:10:00 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

    MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and

    3/26/24 8:00:00 AM ET
    $ADXS
    $IMNM
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Israel Biotech Fund I, L.P.

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    3/6/24 7:13:01 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    2/12/24 2:16:21 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Israel Biotech Fund I, L.P.

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    11/21/23 9:04:41 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Israel Biotech Fund I, L.P. bought 1,317,716 shares (SEC Form 4)

    4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

    10/31/23 7:08:02 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    SEC Filings

    View All

    SEC Form 15-12G filed by Advaxis, Inc.

    15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    5/9/24 4:05:37 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)

    10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    4/26/24 5:03:01 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)

    8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

    4/19/24 7:50:34 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Leadership Updates

    Live Leadership Updates

    View All

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

    SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar

    4/2/21 7:33:00 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    $ADXS
    Financials

    Live finance-specific insights

    View All

    Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

    Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po

    6/5/23 8:00:00 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m

    2/10/23 7:00:31 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

    Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

    10/19/22 6:30:00 AM ET
    $ADXS
    $AYLA
    Major Pharmaceuticals
    Health Care
    Specialty Chemicals
    Consumer Discretionary

    $ADXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

    SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/14/24 4:26:22 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)

    SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/12/24 11:58:05 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

    SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

    2/12/24 8:27:51 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care